Intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada syndrome.

Abstract

PURPOSE:

To report the results of intravitreal triamcinolone acetonide in two eyes of a patient with Vogt-Koyanagi-Harada syndrome.

METHODS:

A 24-year-old woman with Vogt-Koyanagi-Harada syndrome was treated with a single 4-mg dose of intravitreal injection of triamcinolone acetonide in both eyes.

RESULTS:

On the seventh day after injection, visual acuity improved from 20/50 to 20/20 in the right eye and from 20/100 to 20/32 in the left. One month after injection, visual acuity was 20/20 in the right eye and 20/32 in the left, and fluorescein angiography showed that serous detachment had almost completely resorbed. The ocular examination remained stable during the 8-month follow-up period.

CONCLUSIONS:

In this study, a prompt improvement in the clinical picture of a patient with Vogt-Koyanagi-Harada syndrome after intravitreal triamcinolone acetonide injection was described. The results suggest that intravitreal triamcinolone acetonide injection may be an additional tool in the treatment of Vogt-Koyanagi-Harada syndrome.

• Authors: M Karacorlu, S Arf Karacorlu, H Ozdemir
• Journal: European journal of ophthalmology (Eur J Ophthalmol) 2006 May-Jun Vol. 16 Issue 3 Pg. 481-3 ISSN: 1120-6721 [Print] United States
• PMID: 16761256 (Publication Type: Case Reports, Journal Article)

Chemical References

• Glucocorticoids
• Triamcinolone Acetonide

Topics

• Adult
• Female
• Fluorescein Angiography
• Glucocorticoids (therapeutic use)
• Humans
• Injections
• Tomography, Optical Coherence
• Triamcinolone Acetonide (therapeutic use)
• Uveomeningoencephalitic Syndrome (diagnosis, drug therapy)
• Visual Acuity
• Vitreous Body